Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
diagnostics
5
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
merck
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alzheimer's disease
amgen
cancer
gilead sciences
immunotherapy
medicare
pfizer
What
bio
5
×
drug
roundup
acquisitions
biggest
ceo
crispr
new
patients
advantages
albert
approval
bar
biogen’s
biopharmaceutical
bourla
brings
build
buy
companies
company
company’s
convo
create
daniel
debut
diagnostic
diseases
dyne’s
earlier
editing
expect
failures
fix
future
gamble
gene
gilead
heats
high
Language
unset
unknown
Current search:
diagnostics
×
bio
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M